Literature DB >> 8008985

Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer.

M Halme1, P Maasilta, K Mattson, K Cantell.   

Abstract

Eight patients with a thoracic malignancy inhaled single doses of 3-100 x 10(6) IU of human natural interferon (IFN)-beta via a dosimeter-equipped jet nebulizer. After inhalation IFN-beta was not detectable in any of the serum samples as measured using an antiviral bioassay. Except for a slight body temperature rise and an 18% decrease in peak expiratory flow rate observed in 1 patient the patients did not experience any major side effects. Inhaled natural IFN-beta in this study was tolerated better than inhaled IFN-alpha or IFN-gamma in our previous studies. IFN-beta might thus be a promising local treatment for pulmonary diseases. Further work is needed to investigate the concentrations of biologically active IFN in alveolar epithelial lining fluid after inhalation and the therapeutic effect of inhaled IFN-beta.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8008985     DOI: 10.1159/000196316

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  2 in total

1.  Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro.

Authors:  B P Priosoeryanto; S Tateyama; R Yamaguchi; K Uchida
Journal:  Can J Vet Res       Date:  1995-01       Impact factor: 1.310

2.  Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience.

Authors:  Aurélien Mary; Lucie Hénaut; Pierre Yves Macq; Louise Badoux; Arnaud Cappe; Thierry Porée; Myriam Eckes; Hervé Dupont; Michel Brazier
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.